SQZ Biotechnologies (NYSE:SQZ) Expected to Announce Quarterly Sales of $5.41 Million

Analysts forecast that SQZ Biotechnologies (NYSE:SQZGet Rating) will report $5.41 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for SQZ Biotechnologies’ earnings. The highest sales estimate is $5.90 million and the lowest is $4.92 million. SQZ Biotechnologies posted sales of $5.45 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 0.7%. The firm is scheduled to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that SQZ Biotechnologies will report full-year sales of $36.52 million for the current fiscal year, with estimates ranging from $18.00 million to $59.66 million. For the next financial year, analysts expect that the company will post sales of $32.97 million, with estimates ranging from $20.00 million to $40.00 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow SQZ Biotechnologies.

SQZ Biotechnologies (NYSE:SQZGet Rating) last announced its earnings results on Wednesday, March 16th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.26. The business had revenue of $12.35 million for the quarter, compared to analysts’ expectations of $7.99 million. SQZ Biotechnologies had a negative return on equity of 47.47% and a negative net margin of 253.68%.

Shares of SQZ opened at $3.69 on Monday. SQZ Biotechnologies has a 12 month low of $2.73 and a 12 month high of $16.17. The firm’s fifty day simple moving average is $4.47. The stock has a market cap of $103.87 million, a price-to-earnings ratio of -1.49 and a beta of 4.41.

Institutional investors and hedge funds have recently modified their holdings of the company. Temasek Holdings Private Ltd raised its stake in SQZ Biotechnologies by 8.8% in the 3rd quarter. Temasek Holdings Private Ltd now owns 2,758,169 shares of the company’s stock worth $39,773,000 after acquiring an additional 223,993 shares during the last quarter. 683 Capital Management LLC boosted its holdings in shares of SQZ Biotechnologies by 9.4% during the 4th quarter. 683 Capital Management LLC now owns 1,852,135 shares of the company’s stock worth $16,540,000 after purchasing an additional 159,748 shares during the last quarter. NanoDimension Inc. acquired a new position in shares of SQZ Biotechnologies during the 4th quarter worth approximately $12,906,000. BlackRock Inc. boosted its holdings in shares of SQZ Biotechnologies by 13.1% during the 4th quarter. BlackRock Inc. now owns 1,413,870 shares of the company’s stock worth $12,625,000 after purchasing an additional 163,780 shares during the last quarter. Finally, Maverick Capital Ltd. boosted its holdings in shares of SQZ Biotechnologies by 7.5% during the 3rd quarter. Maverick Capital Ltd. now owns 1,056,786 shares of the company’s stock worth $15,239,000 after purchasing an additional 73,690 shares during the last quarter. Hedge funds and other institutional investors own 49.07% of the company’s stock.

SQZ Biotechnologies Company Profile (Get Rating)

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer.

Further Reading

Get a free copy of the Zacks research report on SQZ Biotechnologies (SQZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.